发明授权
- 专利标题： Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
- 专利标题（中）： 优化使用糖皮质激素受体拮抗剂治疗精神障碍患者血浆血清中米非司酮水平
-
申请号： US12199114申请日： 2008-08-27
-
公开(公告)号： US08598149B2公开(公告)日： 2013-12-03
- 发明人: Joseph K. Belanoff
- 申请人： Joseph K. Belanoff
- 申请人地址： US CA Menlo Park
- 专利权人： Corcept Therapeutics, Inc.
- 当前专利权人： Corcept Therapeutics, Inc.
- 当前专利权人地址： US CA Menlo Park
- 代理机构： Kilpatrick Townsend & Stockton LLP.
- 主分类号： A61K31/56
- IPC分类号： A61K31/56
摘要：
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.
公开/授权文献
信息查询
